GlobeNewswire: BioDelivery Sciences International, Inc. Contains the last 10 of 50 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:10:09ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/10/01/1923227/0/en/BioDelivery-Sciences-Announces-Significant-Additional-Insurance-Coverage-for-both-BELBUCA-and-Symproic.html?f=22&fvtc=4&fvtv=43238BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®2019-10-01T12:00:00Z<![CDATA[Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million Lives]]>https://www.globenewswire.com/news-release/2019/09/17/1917030/0/en/BioDelivery-Sciences-Announces-Participation-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=43238BioDelivery Sciences Announces Participation in Upcoming Investor Conferences2019-09-17T20:05:00Z<![CDATA[RALEIGH, N.C., Sept. 17, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that Herm Cukier, Chief Executive Officer, will present at the following investor conferences:]]>https://www.globenewswire.com/news-release/2019/08/29/1908345/0/en/BioDelivery-Sciences-Announces-Upcoming-Investor-Conference-Presentations.html?f=22&fvtc=4&fvtv=43238BioDelivery Sciences Announces Upcoming Investor Conference Presentations2019-08-29T12:00:00Z<![CDATA[RALEIGH, N.C., Aug. 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that Herm Cukier, Chief Executive Officer, will present at the following investor conferences:]]>https://www.globenewswire.com/news-release/2019/08/28/1907673/0/en/BioDelivery-Sciences-Announces-Five-Medical-Abstracts-Accepted-at-PAINWeek-2019-National-Conference-on-Pain-Management.html?f=22&fvtc=4&fvtv=43238BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management2019-08-28T11:45:00Z<![CDATA[New Scientific Information Further Highlights Clinical Profiles of BELBUCA® and Symproic® New Scientific Information Further Highlights Clinical Profiles of BELBUCA® and Symproic®]]>https://www.globenewswire.com/news-release/2019/08/08/1899591/0/en/BioDelivery-Sciences-Reports-Strong-Second-Quarter-2019-Results-and-Raises-Net-Sales-Expectations.html?f=22&fvtc=4&fvtv=43238BioDelivery Sciences Reports Strong Second Quarter 2019 Results and Raises Net Sales Expectations2019-08-08T20:05:00Z<![CDATA[BELBUCA® Net Sales Increased 147% versus Prior Year to All-Time High of $24.1 MillionRaises Full-Year BELBUCA Net Sales Expectations to $90 - $93 MillionRaises Full-Year Total Company Net Sales Expectations to $101 - $105 MillionRaises Long-Term Combined Net Sales Expectations for BELBUCA and Symproic® to $425 - $500 Million]]>https://www.globenewswire.com/news-release/2019/07/30/1893576/0/en/BioDelivery-Sciences-to-Report-Second-Quarter-2019-Financial-Results-and-Host-Conference-Call-on-August-8-2019.html?f=22&fvtc=4&fvtv=43238BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 20192019-07-30T11:45:00Z<![CDATA[RALEIGH, N.C., July 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced its plans to report its second-quarter 2019 financial results after the close of the U.S. financial markets on Thursday, August 8, 2019. The company will host a conference call and webcast at 4:30 PM EDT to discuss the results and provide an update on business operations.]]>https://www.globenewswire.com/news-release/2019/07/09/1880064/0/en/BioDelivery-Sciences-Announces-Further-Improved-Insurance-Coverage-for-BELBUCA.html?f=22&fvtc=4&fvtv=43238BioDelivery Sciences Announces Further Improved Insurance Coverage for BELBUCA® 2019-07-09T12:00:00Z<![CDATA[Regional Commercial Plans Improved Access for More Than 6 Million Lives During 2Q]]>https://www.globenewswire.com/news-release/2019/06/24/1872948/0/en/BioDelivery-Sciences-Expands-Upon-Report-from-Pain-Management-Task-Force.html?f=22&fvtc=4&fvtv=43238BioDelivery Sciences Expands Upon Report from Pain Management Task Force2019-06-24T12:00:00Z<![CDATA[Company’s Activities Support Buprenorphine Recommendations Including:]]>https://www.globenewswire.com/news-release/2019/06/20/1871787/0/en/BioDelivery-Sciences-Named-to-the-Russell-3000-Index.html?f=22&fvtc=4&fvtv=43238BioDelivery Sciences Named to the Russell 3000® Index2019-06-20T12:00:00Z<![CDATA[Recognition is a Result of Company’s Performance over the Last 12 Months Recognition is a Result of Company’s Performance over the Last 12 Months]]>https://www.globenewswire.com/news-release/2019/05/29/1856700/0/en/BioDelivery-Sciences-Announces-Upcoming-Investor-Conference-Presentations.html?f=22&fvtc=4&fvtv=43238BioDelivery Sciences Announces Upcoming Investor Conference Presentations2019-05-29T20:10:00Z<![CDATA[RALEIGH, N.C., May 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions today announced that Herm Cukier, Chief Executive Officer will present at the following investor conferences:]]>